These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15257861)

  • 1. Hypertension management in patients with diabetic nephropathy.
    McCall AL
    Curr Hypertens Rep; 2004 Aug; 6(4):272-9. PubMed ID: 15257861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the management of special populations: renal disease in diabetes.
    Raij L
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
    Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current update in the management of diabetic nephropathy.
    Van Buren PN; Toto R
    Curr Diabetes Rev; 2013 Jan; 9(1):62-77. PubMed ID: 23167665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease.
    Andersen NH; Mogensen CE
    Curr Hypertens Rep; 2004 Oct; 6(5):369-76. PubMed ID: 15341690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
    Majewski C; Bakris GL
    Curr Diab Rep; 2016 Apr; 16(4):24. PubMed ID: 26879307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?].
    Barnas U; Mayer G
    Wien Klin Wochenschr; 1995; 107(1):10-4. PubMed ID: 7871784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common Drugs for Stabilization of Renal Function in the Progression of Diabetic Nephropathy and Their Relations with Hypertension Therapy.
    Wang Y; Wang C; Zhang X; Gu HF; Wu L
    Curr Diabetes Rev; 2018; 14(2):149-161. PubMed ID: 28201968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.
    Van Buren PN; Toto R
    Adv Chronic Kidney Dis; 2011 Jan; 18(1):28-41. PubMed ID: 21224028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
    Yamout H; Lazich I; Bakris GL
    Adv Chronic Kidney Dis; 2014 May; 21(3):281-6. PubMed ID: 24780456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the renin angiotensin system for remission/regression of chronic kidney disease.
    Macconi D
    Histol Histopathol; 2010 May; 25(5):655-68. PubMed ID: 20238303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological prevention and treatment of diabetic nephropathy].
    Aitio ML
    Duodecim; 1993; 109(6):503-11. PubMed ID: 8062718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.